198 Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease – are we missing a trick?

Abstract

mean 4.7 mmol/mol, and results are pending for 18 patients.Collection of outcomes including hospitalisations for HF, CV events, ejection fraction, and adverse effects of treatment is ongoing.The above has been achieved despite limitations imposed by the remote nature of the clinic due to the Covid-19 pandemic, which limits performance of blood tests, echocardiograms and observations. This limitation is expected to be ameliorated by conducting in-person clinics in future. Conclusions Operation of a joint CMC facilitates optimisation of the pharmacological management of risk factors in patients with cardiac and metabolic disease, particularly incorporation of current evidence-based therapies. Emerging outcomes indicate the potential impact of this service on patients' long term CV outcomes.